Daratumumab for refractory posttransplant autoimmune hemolytic anemia: An option beyond the obvious
Autoimmune Cytopenia (AIC) is a complication that occurs in 2-6% of the post-transplant paediatric population. It is a significant cause of morbidity and a therapeutic challenge. The first line treatment is often corticosteroids, and Rituximab is used in the second line. Refractoriness to several li...
Tallennettuna:
| Päätekijät: | , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Wolters Kluwer Medknow Publications
2025-01-01
|
| Sarja: | Annals of Oncology Research and Therapy |
| Aiheet: | |
| Linkit: | https://journals.lww.com/10.4103/aort.aort_30_24 |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|